Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

BACKGROUND: Tofacitinib is the first oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). We compared the effectiveness and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), and non-TNF biologics in patient...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arthritis Res Ther
Glavni autori: Machado, Marina Amaral de Ávila, Moura, Cristiano Soares de, Guerra, Steve Ferreira, Curtis, Jeffrey R., Abrahamowicz, Michal, Bernatsky, Sasha
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865387/
https://ncbi.nlm.nih.gov/pubmed/29566769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1539-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items